Sugi Predict

Sugi Predict / Compounds / SCHEMBL216336

SCHEMBL216336

SCHEMBL216336

CNCCc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]c1=O

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PYGM P11217 3/20 0.61
▸ TK2 O00142 3/20 0.56
▸ DNPH1 O43598 1/20 0.53
▸ SLC28A1 O00337 1/20 0.52
▸ SLC28A2 O43868 1/20 0.52
▸ SLC29A1 Q99808 1/20 0.52
▸ SLC28A3 Q9HAS3 1/20 0.52
▸ TK1 P04183 1/20 0.50
▸ P2RY2 P41231 5/20 0.49
▸ TSHR P16473 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ PMP22 Q01453 1/20 0.44
▸ HBB P68871 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216337 1.00 PYGM (0.61) PYGMTK2DNPH1SLC28A1SLC28A2
SCHEMBL41006 0.88 PYGM (0.63) PYGMTK2DNPH1SLC28A1SLC28A2
SCHEMBL18512922 0.88 PYGM (0.63) PYGMTK2DNPH1SLC28A1SLC28A2
SCHEMBL14853801 0.88 PYGM (0.63) PYGMTK2DNPH1SLC28A1SLC28A2
SCHEMBL14929134 0.88 PYGM (0.63) PYGMTK2DNPH1SLC28A1SLC28A2
SCHEMBL18503552 0.88 PYGM (0.63) PYGMTK2DNPH1SLC28A1SLC28A2
SCHEMBL41007 0.88 PYGM (0.63) PYGMTK2DNPH1SLC28A1SLC28A2
SCHEMBL3416516 0.87 TK2 (0.65) PYGMTK2DNPH1SLC28A1SLC28A2
SCHEMBL1272640 0.87 TK2 (0.65) PYGMTK2DNPH1SLC28A1SLC28A2
SCHEMBL2583312 0.87 TK2 (0.65) PYGMTK2DNPH1SLC28A1SLC28A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705481-A2 CIRCULAR RNA COMPOSITIONS AND METHODS Orna Therapeutics, Inc. (US) 2026-03-11 — — EP claimed
WO-2024233308-A2 CIRCULAR RNA COMPOSITIONS AND METHODS ORNA THERAPEUTICS, INC. (US) 2024-11-14 — — WO claimed
US-11000547-B2 Compositions related to rna in circularized form DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-05-11 — — US claimed
US-10307434-B2 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. (SG) 2019-06-04 — — US claimed
US-20180169146-A1 COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY DANA-FARBER CANCER INSTITUTE, INC. 2018-06-21 — — US claimed
EP-3303377-A1 COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY Dana-Farber Cancer Institute, Inc. (US) 2018-04-11 — — EP claimed
US-9744183-B2 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. (SG) 2017-08-29 — — US claimed
WO-2016197121-A1 COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-08 — — WO claimed
US-9334495-B2 Minor groove binder (MGB)-oligonucleotide miRNA antagonists ELITECHGROUP B.V. (NL) 2016-05-10 — — US claimed
EP-2547769-A1 MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS Elitech Holding B.V. (NL) 2013-01-23 — — EP claimed
US-20110172289-A1 MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS ELITECH HOLDING B.V. 2011-07-14 — — US claimed
WO-2011066312-A1 MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS ELITECH HOLDING B.V. (NL) 2011-06-03 — — WO claimed
US-12637672-B2 Oligonucleotide compositions and methods thereof WAVE LIFE SCIENCES LTD. (SG) 2026-05-26 — — US disclosed
US-20260137713-A1 POLYNUCLEOTIDES FOR SILENCING TRANSCRIPT VARIANT 1 OF ASSEMBLY FACTOR FOR SPINDLE MICROTUBULES AND APPLICATIONS THEREOF TAIPEI MEDICAL UNIVERSITY (TW) 2026-05-21 — — US disclosed
EP-4743437-A1 DIESTER LIPIDS, LIPID NANOPARTICLE CONTAINING DIESTER LIPIDS, AND FORMULATIONS THEREOF Providence Therapeutics Holdings Inc. (CA) 2026-05-20 — — EP disclosed
CN-122031506-A Chiral control 波涛生命科学有限公司 2026-05-15 — — CN disclosed
WO-2004045543-A2 FUNCTIONAL AND HYPERFUNCTIONAL SIRNA DHARMACON, INC. (US) 2004-06-03 — — WO disclosed
EP-0506892-A4 BORONATED NUCLEOSIDES — 1993-03-31 — — EP disclosed
EP-0506892-A1 BORONATED NUCLEOSIDES. BORON BIOLOG INC (US) 1992-10-07 — — EP disclosed
WO-1991009048-A1 BORONATED NUCLEOSIDES BARON BIOLOGICALS, INC. (US) 1991-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137713-A1 POLYNUCLEOTIDES FOR SILENCING TRANSCRIPT VARIANT 1 OF ASSEMBLY FACTOR FOR SPINDLE MICROTUBULES AND APPLICATIONS THEREOF UPF1, NOTCH1, DVL1 PYGM 2240/4885TK2 2746/4885DNPH1 4249/4885
US-20180169146-A1 COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY NSUN2, NSUN3, TRDMT1 PYGM 3962/4885TK2 32/4885DNPH1 4517/4885
US-12637672-B2 Oligonucleotide compositions and methods thereof UPF1, SMN1; SMN2, RNGTT PYGM 15/4885TK2 313/4885DNPH1 3283/4885
US-20110172289-A1 MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS ZFR, SLIRP, CNBP PYGM 3837/4885TK2 3738/4885DNPH1 3929/4885
US-11000547-B2 Compositions related to rna in circularized form NSUN3, METTL16, FBL PYGM 1530/4885TK2 2718/4885DNPH1 2526/4885
US-10307434-B2 Nucleic acid prodrugs and methods of use thereof PNP, RNGTT, NSUN2 PYGM 846/4885TK2 151/4885DNPH1 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.